{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:01:18Z","timestamp":1790730078054,"version":"4.1.0"},"reference-count":38,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Treatment of patients with thyroid cancer with Na[\n                      <jats:sup>131<\/jats:sup>\n                      I]I is routinely performed with empirical activity levels. Treatment success may be expected to correlate with the absorbed doses delivered to targets (thyroid remnants or metastatic lesions), but no systematic review or meta-analysis of absorbed dose\u2013effect relationships has yet been performed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic review and meta-analysis of reports published before August 22, 2025, was performed using PubMed, Web of Science, and OVID MEDLINE. Studies were included if they reported the proportion of patients achieving successful outcome as defined in individual publications and the absorbed doses delivered to targets. The study is registered with PROSPERO (CRD42024554956).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      In total, 3723 studies were identified of which 18 were eligible for analysis. Number of patients in the included studies ranged from 4 to 509. For patients treated with Na[\n                      <jats:sup>131<\/jats:sup>\n                      I]I for thyroid remnant ablation, the reported success rates ranged from 60% to 100%, while lower success rates of 43\u201358% were found for patients with metastatic lesions. Success rates for patients with a thyroid remnant absorbed dose of 300 Gy or more ranged from 78% to 96%, while patients with metastatic lesions receiving at least 80 Gy had success rates ranging from 46% to 98%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      While individual studies have demonstrated the importance of absorbed doses from Na[\n                      <jats:sup>131<\/jats:sup>\n                      I]I for differentiated thyroid cancer, no conclusive absorbed dose\u2013effect relationship has been established in this review. A lack of standardization of dosimetry methodologies and follow-up criteria in the studies obscures the relationship. Large-scale observational prospective studies are required to determine the absorbed doses required for successful personalized treatments of patients with thyroid cancer with Na[\n                      <jats:sup>131<\/jats:sup>\n                      I]I.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10507256251396454","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T10:29:26Z","timestamp":1764152966000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer"],"prefix":"10.1177","volume":"36","author":[{"given":"Jan","family":"Taprogge","sequence":"first","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Murray","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Newbold","sequence":"additional","affiliation":[{"name":"Thyroid Unit, Royal Marsden NHSFT, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Garcez","sequence":"additional","affiliation":[{"name":"Christie NHS Foundation Trust, Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Wadsley","sequence":"additional","affiliation":[{"name":"Weston Park Hospital, Sheffield, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn D.","family":"Flux","sequence":"additional","affiliation":[{"name":"Joint Department of Physics, Royal Marsden NHSFT, Sutton, United Kingdom."},{"name":"The Institute of Cancer Research, London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0597"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02685.x"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-1533"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0666"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1530\/etj-25-0097"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1345"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1261-3"},{"issue":"7","key":"e_1_3_4_9_2","first-page":"1207","article-title":"Iodine-131 treatment of thyroid cancer: Absorbed dose calculated from post-therapy scans","volume":"27","author":"Koral KF","year":"1986","unstructured":"Koral KF, , Adler RS, , Carey JE, et al. Iodine-131 treatment of thyroid cancer: Absorbed dose calculated from post-therapy scans. J Nucl Med, 1986; 27(7):1207\u20131211.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1997.7.183"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(93)90180-g"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.144089"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.170571"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198310203091601"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168799"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0494"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-007-0179-8"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0302"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.11124\/jbies-22-00224"},{"issue":"2","key":"e_1_3_4_21_2","first-page":"136","article-title":"Effects of absorbed dose of (131)vertical bar isotope on the effectiveness of ablation of thyroid remnant tissue","volume":"3","author":"Adamczewski Z","year":"2007","unstructured":"Adamczewski Z, , Makarewicz J, , Lewinski A. Effects of absorbed dose of (131)vertical bar isotope on the effectiveness of ablation of thyroid remnant tissue. Arch Med Sci, 2007; 3(2):136\u2013141.","journal-title":"Arch Med Sci"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960615)77:12<2574::AID-CNCR22>3.0.CO;2-O"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031152"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1076-y"},{"issue":"3","key":"e_1_3_4_25_2","first-page":"451","article-title":"Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach","volume":"44","author":"Dorn R","year":"2003","unstructured":"Dorn R, , Kopp J, , Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med, 2003; 44(3):451\u2013456.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1118\/1.4769426"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-021-01655-y"},{"issue":"12","key":"e_1_3_4_28_2","first-page":"1944","article-title":"Radioiodine therapy for well-differentiated thyroid cancer: A quantitative dosimetric evaluation for remnant thyroid ablation after surgery","volume":"35","author":"Samuel AM","year":"1994","unstructured":"Samuel AM, , Rajashekharrao B. Radioiodine therapy for well-differentiated thyroid cancer: A quantitative dosimetric evaluation for remnant thyroid ablation after surgery. J Nucl Med, 1994; 35(12):1944\u20131950.","journal-title":"J Nucl Med"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93431-1"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3413\/Nukmed-0711-14-12"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050361"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111953"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(18)30306-1"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25295"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00629-4"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264913"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-8140(89)90006-6"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1148\/122.3.731"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1351-2"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256251396454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10507256251396454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10507256251396454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:22Z","timestamp":1787065822000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10507256251396454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"alternative-id":["10.1177\/10507256251396454"],"URL":"https:\/\/doi.org\/10.1177\/10507256251396454","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}